← Eichor
Study identifier: NCT06935357 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Condition: Immunoglobulin A Nephropathy (IgAN)  ·  Sponsor: Biogen

PhasePhase 3
Planned participants454
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease caused by the buildup of an antibody called IgA in the kidneys over time. In people with IgAN, abnormal IgA and other antibodies form clusters that build up in the small filters of the kidneys, which leads to inflammation and damage. Felzartamab is designed to target certain immune cells that produce these abnormal antibodies. This study will focus on participants who have protein in their urine (proteinuria) as a result of damaged kidneys. The main goal of the study is to learn about the effect felzartamab has on proteinuria. The main question that researchers want to answer is: • How much does the amount of protein in the urine change from the start of the study to Week 36? Researchers will learn about the effect felzartamab has on the kidneys' ability to filter blood. They will also learn more about the safety of felzartamab and how it is processed by the body. The study will be done as follows: * Participants will be screened to check if they can join the study. * Participants will be randomized to receive either felzartamab or a placebo. A placebo looks like the study drug but contains no real medicine. * Neither the researchers nor the participants will know what the participants will receive. * Participants will receive felzartamab or placebo as intravenous (IV) infusions. The treatment period will last 24 weeks…

This description comes directly from the study's public registry record.

Talk to the study team

US Biogen Clinical Trial Center  ·  866-633-4636  ·  clinicaltrials@biogen.com

Global Biogen Clinical Trial Center  ·  clinicaltrials@biogen.com

Always discuss trial participation with your own doctor first.

Locations (251)

Applied Research Center of ArkansasLittle Rock, Arkansas, United StatesRecruiting
Kidney & Hypertension Center - Apple ValleyApple Valley, California, United StatesRecruiting
Scripps Green HospitalCarlsbad, California, United StatesRecruiting
National Institute of clinical Research Administration OfficeGarden Grove, California, United StatesWithdrawn
UCLA Health David Geffen School of MedicineLos Angeles, California, United StatesRecruiting
FOMAT Medical Research - FOMAT - PPDSOxnard, California, United StatesRecruiting
North America Research Institute-San DimasSan Dimas, California, United StatesRecruiting
Nova Clinical Research, LLCBradenton, Florida, United StatesRecruiting
University of Florida - Gainesville - 1600 SW Archer RdGainesville, Florida, United StatesNot Yet Recruiting
Royal Research, Corp.Hollywood, Florida, United StatesRecruiting
Central Florida Kidney SpecialistsOrlando, Florida, United StatesRecruiting
CDC Research Institute, LLCPort Saint Lucie, Florida, United StatesRecruiting

+ 239 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06935357